High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 22, Issue 3, 1998, Pages 259-264

  Simpson, D R ^a   Nevill, T J ^a,c   Shepherd, J D ^a   Fung, H C ^a   Horsman, D E ^a   Nantel, S H ^a   Vickars, L M ^a   Sutherland, H J ^a   Toze, C L ^a   Hogge, D E ^a   Klingemann, H G ^a   Naiman, S C ^b   Barnett, M J ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Acute myelogenous leukemia; Allogeneic BMT; Extramedullary relapse

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RISK; STEM CELL TRANSPLANTATION; SURVIVAL;

EID: 0031854709     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701319     Document Type: Article

References (43)

1. Clift RA. Buckner CD, Thomas ED et al. The treatment of non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 243-258.
2. Gratwohl A, Hermans J, Barrett AF et al. Allogeneic bone marrow transplantation for leukaemia in Europe. Lancet 1988; 1: 1379-1382.
3. Gale RP, Horowitz MM, Biggs JC et al. Transplant or chemotherapy in acute myelogenous leukaemia. Lancet 1989; 1: 1119-1122.
4. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1353.
5. McGlave PB, Haake RJ, Bodstrom BC et al. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood 1988; 72: 1512-1517.
6. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation for acute myeloid leukemia in first remission with two irradiation regimens. Blood 1990; 76: 1867-1871.
7. Biaise D, Maraninchi D, Archimbaud E et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission; a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the groupe d'etudes de la greffe de moelle osseuse. Blood 1992; 79: 2578-2582.
8. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic bone marrow transplant group. Blood 1994; 83: 2723-2730.
9. Keating A, Rowlings PA, Horowitz MM et al. Comparison of HLA-identical sibling and autologous bone marrow transplants for acute myelogenous leukemia (AML). Blood 1994; 84 (Suppl. 1): 201a (Abstr. 789).
10. Blume KG, Beutler E, Bross KJ et al. Bone marrow ablation and allogeneic marrow transplantation in acute leukemia. New Engl J Med 1980; 302: 1041-1046.
11. Forman SJ, Schmidt GM, Nademanee AP et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol 1991; 9: 1570-1574.
12. Mortimer J, Blinder MA, Schul man S et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989: 7: 50-57.
13. Bekassy AN, Hermans J, Gorin NC et al. Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Bone Marrow Transplant 1996; 7: 801-808.
14. Grigg A, Shepherd JD, Phillips GL. Busulphan and phenytoin. Ann Intern Med 1989; 111: 1049-1050 (letter) (correction in Ann Intern Med 1990; 112: 313).
15. Grigg A, Shepherd JD, Phillips GL. Busulphan and phenytoin. Ann Intern Med 1989; 111: 1049-1050 (letter) (correction in Ann Intern Med 1990; 112: 313).
16. Shepherd JD, Pringle LE, Bamett MJ et al. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhasic cystitis in bone marrow transplantation. J Clin Oncol 1991; 9: 2016-2020.
17. Warkentin PI, Hilden JM, Kersey JH et al. Transplantation of major ABO compatible bone marrow depleted of red cells by hydroxyethyl starch. Vox Sang 1985; 48: 89-104.
18. Nevill TJ, Tirgan MH, Deeg JH et al. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 9: 349-354.
19. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
20. Shepherd JD, Shore TB, Reece DE et al. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant 1988; 3: 553-558.
21. Phillips GL, Nevill TJ, Spinelli JJ et al. Prophylaxis for acute graft-versus-host disease following unrelated-donor bone marrow transplantation. Bone Marrow Transplant 1995; 15: 213-219.
22. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
23. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graftversus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
24. Attal M, Huguet F, Rubie H et al. Prevention of hepatic venoocclusive disease after bone marrow transplantation by continuous infusion low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834-2840.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
26. Witherspoon R, Fluornoy N, Thomas ED et al. Recurrence of acute leukemia more than two years after allogeneic marrow grafting. Exp Hematol 1986; 14: 178-181.
27. Socie G, Sobocinski K, Veum-Stone J et al. Long-term survival and analysis of late causes of death after allogeneic bone marrow transplantation (BMT). Blood 1996; 88 (Suppl. 1): 643a (Abstr. 2561).
28. Frassoni F, Labopin M, Gluckman E et al. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Leukemia 1994; 8: 924-928.
29. Byrd JC, Edenfield WJ, Shields DJ et al. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 1995; 13: 1800-1816.
30. Byrd JC, Weiss RB. Recurrent granulocytic sarcoma: an unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule. Cancer 1994; 73: 2107-2112.
31. Byrd JC, Weiss RB, Arthur DC et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol 1997; 15: 466-475.
32. Wiernik PH, De Bellis R, Muxi P et al. Extramedullary acute promyelocytic leukemia. Cancer 1996; 78: 2510-2514.
33. Forrest DL, Dalal BI, Naiman SC et al. Testicular relapse of acute promyelocytic leukemia after allogeneic BMT. Bone Marrow Transplant 1997; 20: 689-690.
34. Hiorns LR, Swansbury GJ, Mehta J et al. Additional chromosomal abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 1997; 96: 314-321.
35. Kobayashi M, Imamura M, Soga R et al. Establishment of a novel granulocytic sarcoma cell line which adhere to dermal fibroblasts from a patient with granulocytic sarcoma in dermal tissues and myelofibrosis. Br J Haematol 1992; 83: 26-31.
36. Lehman LE, Guinan EC, Halpern SL et al. Isolated testicular relapse in an adolescent 5 years following allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1997; 19: 849-851.
37. Buggia I, Locatelli F, Regazzi M et al. Busulfan. Ann Pharmacother 1994; 28: 1055-1062.
38. Grochow L. Busulfan disposition: the role for therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20 (Suppl. 4): 18-25.
39. Embree L, Fung H, Barnett MJ et al. Lack of association between busulfan AUC and hepatic veno-occlusive disease (submitted for publication).
40. Hassan M, Ljungman P, Bolme P et al. Busulfan and bioavailability. Blood 1994; 84: 2144-2150.
41. Hassan M, Oberg G, Bjorkholm M et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-186.
42. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055-3060.
43. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994; 84: 3603-3612.